536 related articles for article (PubMed ID: 29556394)
1. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential.
Gan L; Yang Y; Li Q; Feng Y; Liu T; Guo W
Biomark Res; 2018; 6():10. PubMed ID: 29556394
[TBL] [Abstract][Full Text] [Related]
2. EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?
Yan KS; Lin CY; Liao TW; Peng CM; Lee SC; Liu YJ; Chan WP; Chou RH
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561778
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
Christofides A; Karantanos T; Bardhan K; Boussiotis VA
Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
[TBL] [Abstract][Full Text] [Related]
4. Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.
Gautam N; Kaur M; Kaur S
J Cancer Res Ther; 2021; 17(2):311-326. PubMed ID: 33063698
[TBL] [Abstract][Full Text] [Related]
5. Regulation and role of post-translational modifications of enhancer of zeste homologue 2 in cancer development.
Lu H; Li G; Zhou C; Jin W; Qian X; Wang Z; Pan H; Jin H; Wang X
Am J Cancer Res; 2016; 6(12):2737-2754. PubMed ID: 28042497
[TBL] [Abstract][Full Text] [Related]
6. Regulation and Role of EZH2 in Cancer.
Yamaguchi H; Hung MC
Cancer Res Treat; 2014 Jul; 46(3):209-22. PubMed ID: 25038756
[TBL] [Abstract][Full Text] [Related]
7. Regulation of T Cell Differentiation and Function by EZH2.
Karantanos T; Chistofides A; Barhdan K; Li L; Boussiotis VA
Front Immunol; 2016; 7():172. PubMed ID: 27199994
[TBL] [Abstract][Full Text] [Related]
8. Role of EZH2 in bone marrow mesenchymal stem cells and immune-cancer interactions.
Liu Z; Jia Y; Guo Y; Wang H; Fu R
Crit Rev Oncol Hematol; 2022 Jan; 169():103547. PubMed ID: 34843930
[TBL] [Abstract][Full Text] [Related]
9. Targeting histone methyltransferase EZH2 as cancer treatment.
Kondo Y
J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
[TBL] [Abstract][Full Text] [Related]
10. Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.
Marchesi I; Bagella L
World J Clin Oncol; 2016 Apr; 7(2):135-48. PubMed ID: 27081636
[TBL] [Abstract][Full Text] [Related]
11. EZH2: a novel target for cancer treatment.
Duan R; Du W; Guo W
J Hematol Oncol; 2020 Jul; 13(1):104. PubMed ID: 32723346
[TBL] [Abstract][Full Text] [Related]
12. EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys
Huang JP; Ling K
Oncol Lett; 2017 Nov; 14(5):5735-5742. PubMed ID: 29113202
[TBL] [Abstract][Full Text] [Related]
13. Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity.
Alzrigat M; Jernberg-Wiklund H; Licht JD
Epigenomes; 2018 Sep; 2(3):. PubMed ID: 30761216
[TBL] [Abstract][Full Text] [Related]
14. Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus.
Jie B; Weilong C; Ming C; Fei X; Xinghua L; Junhua C; Guobin W; Kaixiong T; Xiaoming S
Int J Biochem Cell Biol; 2015 Aug; 65():104-12. PubMed ID: 26004298
[TBL] [Abstract][Full Text] [Related]
15. Quantification of histone H3 Lys27 trimethylation (H3K27me3) by high-throughput microscopy enables cellular large-scale screening for small-molecule EZH2 inhibitors.
Luense S; Denner P; Fernández-Montalván A; Hartung I; Husemann M; Stresemann C; Prechtl S
J Biomol Screen; 2015 Feb; 20(2):190-201. PubMed ID: 25409661
[TBL] [Abstract][Full Text] [Related]
16. The Roles of the Histone Protein Modifier EZH2 in the Uterus and Placenta.
Mesa AM; Rosenfeld CS; Tuteja G; Medrano TI; Cooke PS
Epigenomes; 2020 Sep; 4(3):. PubMed ID: 33732505
[TBL] [Abstract][Full Text] [Related]
17. EZH2 is involved in silencing of WNT5A during epithelial-mesenchymal transition of colon cancer cell line.
Tao J; Shi L; Huang L; Shi H; Chen H; Wang Y; Wang T
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2211-2219. PubMed ID: 28748258
[TBL] [Abstract][Full Text] [Related]
18. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.
Cardenas H; Zhao J; Vieth E; Nephew KP; Matei D
Oncotarget; 2016 Dec; 7(51):84453-84467. PubMed ID: 27563817
[TBL] [Abstract][Full Text] [Related]
19. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
[TBL] [Abstract][Full Text] [Related]
20. EZH2: a pivotal regulator in controlling cell differentiation.
Chen YH; Hung MC; Li LY
Am J Transl Res; 2012; 4(4):364-75. PubMed ID: 23145205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
